

# Left ventricular remodelling patterns in patients with moderate aortic stenosis

Jan Stassen <sup>1,2</sup>, See Hooi Ewe <sup>3</sup>, Kensuke Hirasawa <sup>1</sup>, Steele C. Butcher<sup>1,4</sup>, Gurpreet K. Singh<sup>1</sup>, Mohammed R. Amanullah<sup>3</sup>, Kenny Y.K. Sin<sup>3</sup>, Zee P. Ding<sup>3</sup>, Stephan M. Pio<sup>1</sup>, Nicholas W.S. Chew <sup>5</sup>, Ching-Hui Sia <sup>5</sup>, William K.F. Kong<sup>5</sup>, Kian Keong Poh<sup>5</sup>, David J. Cohen<sup>6,7</sup>, Philippe Généreux<sup>8</sup>, Martin B. Leon<sup>9</sup>, Nina Ajmone Marsan<sup>1</sup>, Victoria Delgado <sup>1</sup>, and Jeroen J. Bax<sup>1,10\*</sup>

<sup>1</sup>Department of Cardiology, Leiden University Medical Center, Albinusdreef 2, 2300 RC Leiden, The Netherlands; <sup>2</sup>Department of Cardiology, Jessa Hospital, Hasselt, Belgium; <sup>3</sup>Department of Cardiology, National Heart Centre Singapore, Singapore; <sup>4</sup>Department of Cardiology, Royal Perth Hospital, Perth, Western Australia, Australia; <sup>5</sup>Department of Cardiology, National University Heart Center Singapore, Singapore; <sup>6</sup>Department of Cardiology, Saint Francis Hospital, Roslyn, NY, USA; <sup>7</sup>Department of Cardiology, Cardiovascular Research Foundation, New York, NY, USA; <sup>8</sup>Department of Cardiology, Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, NJ, USA; <sup>9</sup>Department of Cardiology, Columbia University Irving Medical Center/New York—Presbyterian Hospital, Cardiovascular Research Foundation, New York, NY, USA; and <sup>10</sup>Department of Cardiology, Turku Heart Center, University of Turku, Turku University Hospital, Turku, Finland

Received 9 December 2021; editorial decision 17 January 2022; accepted 26 January 2022; online publish-ahead-of-print 18 February 2022

## Aims

Moderate aortic stenosis (AS) is associated with an increased risk of adverse events. Because outcomes in patients with AS are ultimately driven by the condition of the left ventricle (LV) and not by the valve, assessment of LV remodelling seems important for risk stratification. This study evaluated the association between different LV remodelling patterns and outcomes in patients with moderate AS.

## Methods and results

Patients with moderate AS (aortic valve area 1.0–1.5 cm<sup>2</sup>) were identified and stratified into four groups according to the LV remodelling pattern: normal geometry (NG), concentric remodelling (CR), concentric hypertrophy (CH), or eccentric hypertrophy (EH). Clinical outcomes were defined as all-cause mortality and a composite endpoint of all-cause mortality and aortic valve replacement (AVR). Of 1931 patients with moderate AS (age 73 ± 10 years, 52% men), 344 (18%) had NG, 469 (24%) CR, 698 (36%) CH, and 420 (22%) EH. Patients with CH and EH showed higher 3-year mortality rates (28% and 32%, respectively) when compared with patients with NG (19%) ( $P < 0.001$ ). After multivariable adjustment, CH remained independently associated with mortality (HR 1.258, 95% CI 1.016–1.558;  $P = 0.035$ ), whereas both CH (HR 1.291, 95% CI 1.088–1.532;  $P = 0.003$ ) and EH (HR 1.217, 95% CI 1.008–1.470;  $P = 0.042$ ) were associated with the composite endpoint of death or AVR.

## Conclusion


In patients with moderate AS, those who develop CH already have an increased risk of all-cause mortality. Assessment of the LV remodelling patterns may identify patients at higher risk of adverse events, warranting closer surveillance, and possibly earlier intervention.

\* Corresponding author. Tel: +31 71 526 2020; Fax: +31 71 526 6809. E-mail: [jj.bax@lumc.nl](mailto:jj.bax@lumc.nl)

© The Author(s) 2022. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Graphical Abstract



Number at risk		0	12	24	36	48	60	72	84	96	108	120
—	Normal geometry	344	307	270	237	191	149	112	82	57	38	29
—	Concentric remodeling	469	415	365	313	258	198	159	122	93	66	49
—	Concentric hypertrophy	698	598	509	447	356	278	204	156	111	86	59
—	Eccentric hypertrophy	420	356	306	259	215	168	131	100	72	57	41

Left ventricular remodeling is already frequently observed in patients with moderate aortic stenosis and is strongly associated with outcomes.

**Keywords** moderate aortic stenosis • left ventricular remodelling • mortality • aortic valve replacement

Introduction

Aortic stenosis (AS) is the most common valvular heart disease in developed countries, affecting 4–5% of patients aged over 65 years.<sup>1,2</sup> It is well established that symptomatic severe AS is associated with significantly worse survival if left untreated.<sup>3–5</sup> Recently, less favourable clinical outcomes have also been reported in patients with moderate AS.<sup>6,7</sup> Hence, identifying patients with moderate AS at higher mortality risk and who may benefit from close surveillance seems

crucial. Although risk stratification in AS has traditionally been based on symptoms and left ventricular (LV) ejection fraction (EF),<sup>8,9</sup> the LV remodelling response to AS-related pressure overload is noted before a reduction in LVEF occurs, with several studies demonstrating that LV structural changes are already apparent despite preserved LVEF.<sup>10,11</sup> Moreover, adverse LV remodelling is an important predictor of cardiovascular morbidity and mortality in many cardiovascular diseases,<sup>12–14</sup> including severe AS.<sup>15,16</sup> Indeed, while LV remodelling is initially a benign response to increased wall stress, it eventually may

lead to development of myocardial fibrosis with a progressive deterioration in LV diastolic relaxation and performance, which are both associated with adverse clinical outcomes in severe AS.<sup>10,17–19</sup> In addition, patients with LV hypertrophy may not always show reverse LV remodelling after aortic valve replacement (AVR), leading to worse postoperative outcomes. These observations underscore the need to identify echocardiographic parameters beyond LVEF to detect the consequences of AS afterload on the LV. Current guidelines recognize four patterns of LV remodelling that could be used to describe the LV response to AS: normal geometry, concentric remodelling, concentric hypertrophy, and eccentric hypertrophy.<sup>20</sup> The prognostic implications of these four patterns of LV remodelling in patients with moderate AS, however, have not been investigated. In this study, we aimed to investigate the clinical and echocardiographic characteristics of these four LV remodelling patterns and their prognostic implications in patients with moderate AS.


## Methods

### Patient population

From the ongoing registries of patients with moderate aortic valve disease from three academic institutions (Leiden University Medical Center, Leiden, The Netherlands, National University Hospital, Singapore and National Heart Center Singapore, Singapore), patients  $\geq 18$  years who presented between October 2001 and December 2019 with a first echocardiographic diagnosis of moderate AS were identified. Moderate AS was defined as an aortic valve area (AVA) between 1.0 and 1.5 cm<sup>2</sup>.<sup>8</sup> The definition of moderate AS based on aortic valve area was used to avoid inclusion of patients with severe, low-flow, low-gradient AS and was based on previous papers.<sup>21,22</sup> Patients with previous aortic valve surgery, congenital heart disease, bicuspid aortic valve, supra- or subvalvular AS, or dynamic LV outflow tract obstruction were excluded. All patients underwent complete clinical and echocardiographic evaluation at the time of first diagnosis of moderate AS. Patient information was prospectively collected from the departmental cardiology information system and retrospectively analysed. Clinical data included demographic characteristics, cardiovascular risk factors, New York Heart Association (NYHA) functional class, and comorbidities. The study complies with the Declaration of Helsinki and was approved by the institutional review boards of each centre. Due to the retrospective design of the study, the medical ethics committee of each participating centre waived the need for written informed consent.

### Transthoracic echocardiography

All echocardiographic studies were performed using commercially available ultrasound systems and images were retrospectively analysed in each centre according to current guidelines.<sup>20</sup> In the parasternal long-axis view, LV dimensions were assessed, and LV mass was calculated using Devereux's formula and indexed for body surface area (LVMI).<sup>20</sup> Relative wall thickness (RWT) was calculated with the formula:  $(2 \times \text{posterior wall thickness})/(\text{LV internal diameter at end-diastole})$ .<sup>20</sup> The echocardiographic variables that define LV geometry (LVMI and RWT) were subsequently used to categorize patients into four patterns of LV remodelling: normal geometry (normal LVMI and RWT  $\leq 0.42$ ), concentric remodelling (normal LVMI and RWT  $> 0.42$ ), concentric hypertrophy (increased LVMI and RWT  $> 0.42$ ), and eccentric hypertrophy (increased LVMI and RWT  $\leq 0.42$ ).<sup>20</sup> (Figure 1). Normal LVMI was defined as LVMI  $\leq 95$  g/m<sup>2</sup> for women and LVMI  $\leq 115$  g/m<sup>2</sup> for men.<sup>20</sup> LV volumes were assessed



**Figure 1** Basic patterns of left ventricular remodelling.

and LVEF was calculated according to biplane Simpson's method.<sup>20</sup> Left atrial volumes were measured by the biplane method of disks and indexed for body surface area.<sup>20</sup> From the apical three- or five-chamber views, continuous-wave Doppler recordings were obtained to estimate peak aortic jet velocity.<sup>23</sup> Mean and peak transvalvular pressure gradients were calculated using the Bernoulli equation.<sup>23</sup> AVA was calculated using the LV outflow tract diameter and velocity time integrals of the aortic valve and LV outflow tract.<sup>23</sup> Severity of mitral and tricuspid regurgitation was graded using a multiparametric approach, as recommended by current guidelines.<sup>24</sup> Pulsed-wave Doppler recordings of the transmitral flow were used to obtain peak early (E) and late (A) diastolic velocities.<sup>25</sup> Using tissue Doppler imaging of the mitral annulus on the apical four-chamber view, the  $e'$  was measured at both the lateral and septal side, and averaged to calculate the  $E/e'$  ratio.<sup>25</sup> The right ventricular systolic pressure was calculated from the peak velocity of the tricuspid regurgitant jet according to the Bernoulli equation, by adding the right atrial pressure determined by the inspiratory collapse and diameter of the inferior vena cava.<sup>20,26</sup> For the evaluation of right ventricular systolic function, anatomical M-mode was applied to the focused apical four-chamber view of the right ventricle to measure tricuspid annular plane systolic excursion.<sup>26</sup>

### Clinical endpoints

All patients were followed-up for all-cause mortality and the occurrence of AVR (either surgical or transcatheter). The primary outcome was all-cause mortality, which was obtained by review of hospital records linked to the governmental death registry database.

### Statistical analysis

Continuous data are presented as mean  $\pm$  standard deviation when normally distributed and as median (interquartile range) when not normally distributed. Categorical data are presented as frequencies and percentages. For comparison of continuous variables between groups, the one-way analysis of variance with Bonferroni's *post hoc* analysis or the Kruskal–Wallis test was used for normally and non-normally distributed variables, respectively. Categorical variables were compared using the Pearson  $\chi^2$  test. The inter- and intra-observer variability of LVMI was assessed by calculating the intra-class correlation coefficient on 50 randomly selected patients. The intra-class correlation coefficients for inter- and intra-observer variability were 0.91 [95% confidence interval (CI) 0.88–0.98;  $P < 0.001$ ] and 0.94 (95% CI 0.86–0.97;  $P < 0.001$ ), respectively. Event-free survival curves were generated using the Kaplan–Meier



**Table 1** Clinical characteristics of the total study population and according to different patterns of LV remodelling

Variables	Total population (n = 1931)	Normal geometry (n = 344)	Concentric remodelling (n = 469)	Concentric hypertrophy (n = 698)	Eccentric hypertrophy (n = 420)	P- value
Age (years)	73.2 (± 10.3)	71.9 (± 11.4)	74.3 (± 10.0)*	73.9 (± 9.7)*	72.1 (± 10.5)***	<0.001
Male sex (%)	995 (51.5)	200 (58.1)	285 (60.8)	296 (42.2)***	214 (51.0)***	<0.001
Arterial hypertension (%)	1546 (80.3)	270 (78.5)	359 (76.7)	588 (84.4)**	329 (78.9)	0.006
Dyslipidaemia (%)	1428 (74.3)	254 (73.8)	339 (72.6)	529 (76.1)	306 (73.4)	0.545
DM (%)	661 (34.3)	112 (32.6)	161 (34.4)	252 (36.2)	136 (32.6)	0.561
Current smoker (%)	173 (9.3)	35 (10.6)	31 (7.0)	62 (9.3)	45 (10.9)	0.202
Obesity (BMI ≥30 kg/m <sup>2</sup> ) (%)	366 (19.0)	61 (17.7)	87 (18.6)	146 (20.9)	72 (17.1)	0.387
CAD (%)	865 (44.9)	158 (45.9)	184 (39.3)	319 (45.7)	204 (48.8)**	0.032
Previous MI (%)	362 (18.8)	65 (19.0)	63 (13.5)	124 (17.8)	110 (26.3)***	<0.001
Atrial fibrillation (%)	552 (28.6)	86 (25.0)	119 (25.4)	211 (30.2)	136 (32.6)	0.034
Previous stroke (%)	285 (14.8)	48 (14.0)	63 (13.5)	109 (15.6)	65 (15.5)	0.706
COPD (%)	142 (7.4)	25 (7.3)	35 (7.5)	47 (6.7)	35 (8.4)	0.788
NYHA class II–IV (%)	828 (43.4)	135 (39.7)	188 (40.4)	305 (44.3)	200 (48.1)	0.057
NYHA class III–IV (%)	321 (16.8)	49 (14.4)	57 (12.3)	126 (18.3)**	89 (21.4)**	0.001
Angina (%)	162 (8.5)	24 (7.0)	38 (8.2)	50 (7.3)	50 (12.0)***	0.030
Syncope (%)	30 (1.6)	7 (2.1)	9 (1.9)	8 (1.2)	6 (1.4)	0.641
Beta-blocker (%)	949 (49.4)	165 (48.0)	217 (46.5)	343 (49.6)	224 (53.6)	0.184
ACEi or ARB (%)	957 (49.8)	165 (48.0)	215 (46.0)	365 (52.8)	212 (50.7)	0.123
MRA (%)	109 (5.7)	19 (5.6)	18 (3.9)	29 (4.2)	43 (10.3)***	<0.001
Diuretic (%)	661 (34.4)	101 (29.4)	137 (29.3)	236 (34.2)	187 (44.7)***	<0.001
CCB (%)	757 (39.4)	128 (37.2)	164 (35.1)	315 (45.6)**	150 (35.9)	0.001
Statin (%)	1340 (69.8)	250 (72.7)	323 (69.2)	484 (70.0)	283 (67.7)	0.507
Aspirin (%)	904 (47.1)	160 (46.5)	222 (47.5)	324 (46.9)	198 (47.4)	0.991
Oral anticoagulation (%)	387 (20.2)	62 (18.0)	88 (18.8)	131 (19.0)	106 (25.4)	0.028
eGFR (mL/min/1.73 m <sup>2</sup> )	67 (44–87)	74 (53–93)	71.4 (53–90)	61 (35–83)***	66 (40–86)***	<0.001
Haemoglobin (g/dL)	12.5 (11.0–13.7)	12.5 (10.9–13.7)	13.0 (11.6–14.1)**	12.1 (10.6–13.4)**	12.4 (11.0–13.6)**	<0.001

Values are presented as mean ± SD, median (IQR), or n (%).

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.

\*P < 0.05 vs. Group I.

\*\*P < 0.05 vs. Group II.


\*\*\*P < 0.05 vs. Group III.

**Table 2** Echocardiographic characteristics of the total study population and according to different patterns of remodelling

Variables	Total population (n = 1931)	Normal geometry (n = 344)	Concentric remodelling (n = 469)	Concentric hypertrophy (n = 698)	Eccentric hypertrophy (n = 420)	P- value
LV EDD (mm)	48.0 (± 7.2)	48.1 (± 5.0)*	41.8 (± 4.6)*	47.3 (± 5.5)**	55.7 (± 6.3)***	<0.001
LV ESV (mL)	38 (28–53)	40 (32–51)	30 (22–38)*	38 (28–50)**	58 (41–85)***	<0.001
LV EDV (mL)	98 (79–124)	99 (85–118)	80 (66–97)*	97 (79–118)**	131 (107–156)***	<0.001
LVEF (%)	58.2 (± 12.6)	58.0 (± 11.7)	62.3 (± 9.4)*	59.6 (± 11.2)**	51.4 (± 15.7)***	<0.001
LVMi (g/m <sup>2</sup> )	115.9 (± 34.8)	85.9 (± 15.0)	88.3 (± 14.6)	135.7 (± 29.3)***	138.3 (± 31.3)***	<0.001
LAVi (mL/m <sup>2</sup> )	37 (29–47)	33 (28–43)	32 (26–41)	39 (31–49)***	42 (34–53)***	<0.001
E/e'	14.5 (10.9–20.0)	13.1 (9.6–17.5)	13.0 (9.8–18.0)	15.2 (11.6–20.8)***	16.6 (12.3–21.8)***	<0.001
Moderate or severe MR (%)	181 (9.4)	34 (9.9)	14 (3.0)*	58 (8.3)**	75 (17.9)***	<0.001
Stroke volume index (mL/m <sup>2</sup> )	48.2 (± 13.1)	46.4 (± 12.8)	46.6 (± 11.3)	50.2 (± 12.0)**	48.3 (± 16.0)	<0.001
Peak aortic velocity (m/s)	3.0 (± 0.6)	2.9 (± 0.6)	3.1 (± 0.6)*	3.1 (± 0.6)*	3.0 (± 0.6)***	<0.001
Aortic mean pressure gradient (mmHg)	22.7 (± 8.6)	21.3 (± 8.1)	23.0 (± 8.5)*	23.8 (± 8.6)*	21.9 (± 9.0)***	<0.001
Aortic valve area (cm)	1.22 (± 0.15)	1.23 (± 0.15)	1.23 (± 0.15)	1.21 (± 0.15)	1.22 (± 0.15)	0.091
Moderate or severe AR (%)	210 (10.9)	31 (9.0)	41 (8.7)	71 (10.2)	67 (16.0)***	0.002
TAPSE (mm)	21 (19–24)	22 (19–25)	22 (19–25)	21 (18–24)	20 (18–24)***	0.005
PASP (mmHg)	33 (27–42)	33 (26–41)	32 (25–38)	33 (28–42)**	36 (28–46)***	<0.001
Moderate or severe TR (%)	313 (16.3)	57 (16.7)	69 (14.8)	101 (14.6)	86 (20.6)	0.050

Values are presented as mean ± SD, median (IQR), or n (%). AR, aortic regurgitation; EDD, end-diastolic diameter; EDV, end-diastolic volume; EF, ejection fraction; ESD, end-systolic diameter; LAVi, left atrial volume index; LV, left ventricular; LVMi, left ventricular mass index; MR, mitral regurgitation; PASP, pulmonary artery systolic pressure; TAPSE, tricuspid annular plane systolic excursion; TR, tricuspid regurgitation.  
 \*p < 0.05 vs. Group I.  
 \*\*p < 0.05 vs. Group II.  
 \*\*\*p < 0.05 vs. Group III.





**Figure 2** Kaplan–Meier curves for all-cause mortality (A) and the composite endpoint of death and AVR (B) according to different patterns of LV remodelling. AVR, aortic valve replacement; LV, left ventricular.

## Discussion

The main findings of this study with data obtained from a large registry of patients with moderate AS can be summarized as follows: (i) LV remodelling varies significantly in patients with moderate AS, and (ii) LV concentric hypertrophy is independently associated with all-cause mortality after adjusting for various clinical and echocardiographic variables.

### LV remodelling in moderate AS

Although LV remodelling is considered a compensatory mechanism to reduce wall stress and maintain LVEF in AS, it eventually becomes maladaptive, leading to a progressive impairment in LV diastolic

relaxation and LV performance which are both associated with worse outcomes in patients with AS.<sup>17–19,27</sup> Indeed, as the LV hypertrophies, myocardial oxygen demand increases while coronary flow reserve decreases due to concomitant microvascular dysfunction, low coronary perfusion pressure, increased extravascular compressive forces, and reduced diastolic perfusion time.<sup>28,29</sup> This disbalance between oxygen demand and delivery eventually causes ischaemia and leads to LV myocardial fibrosis, which is known to be a major determinant of clinical progression from compensated LV hypertrophy to heart failure and is independently associated with mortality in patients with severe AS.<sup>10,30–32</sup> Previous studies have already demonstrated the association between LV mass and LV myocardial fibrosis detected by CMR,<sup>32</sup> which could explain why a higher LV mass

**Table 3** Univariable and multivariable Cox regression analysis for all-cause mortality and the composite endpoint of death and AVR

	All-cause mortality		AVR or all-cause mortality	
	HR (95% CI)	P value	HR (95% CI)	P value
	Univariable analysis		Univariable analysis	
Normal geometry	Reference group		Reference group	
Concentric remodelling	0.976 (0.773–1.233)	0.840	1.103 (0.922–1.319)	0.282
Concentric hypertrophy	1.410 (1.147–1.734)	0.001	1.285 (1.091–1.513)	0.003
Eccentric hypertrophy	1.435 (1.148–1.793)	0.002	1.300 (1.087–1.555)	0.004
	Multivariable analysis <sup>a</sup>		Multivariable analysis <sup>b</sup>	
Normal geometry	Reference group		Reference group	
Concentric remodelling	0.973 (0.763–1.240)	0.825	1.111 (0.921–1.342)	0.272
Concentric hypertrophy	1.258 (1.016–1.558)	0.035	1.291 (1.088–1.532)	0.003
Eccentric hypertrophy	1.244 (0.987–1.568)	0.065	1.217 (1.008–1.470)	0.042

AVR, aortic valve replacement; CI, confidence interval; HR, hazard ratio.

<sup>a</sup>Adjusted for age, sex, arterial hypertension, diabetes mellitus, hyperlipidaemia, coronary artery disease, previous myocardial infarction, atrial fibrillation, estimated glomerular filtration rate, NYHA class  $\geq 2$ , left ventricular ejection fraction, left atrial volume index, aortic valve area, and SAVR/TAVR as a time-dependent covariate.

<sup>b</sup>Adjusted for age, sex, arterial hypertension, diabetes mellitus, hyperlipidaemia, coronary artery disease, previous myocardial infarction, atrial fibrillation, estimated glomerular filtration rate, NYHA class  $\geq 2$ , left ventricular ejection fraction, left atrial volume index, and aortic valve area.

detected by echocardiography is associated with an increased risk of heart failure in AS<sup>33</sup> and is associated with worse outcomes in this study.

Although AVR relieves the imposed valvular afterload on the LV, LV diastolic dysfunction may persist due to the underlying presence of irreversible LV myocardial fibrosis. Therefore, end-diastolic LV pressure remains high after AVR and this could generate a vicious cycle of reduced coronary artery perfusion with further progression of LV mid-wall fibrosis. These findings might explain why maladaptive LV remodelling does not necessarily reverse after AVR.<sup>10,27,34–36</sup> In addition, if no timely intervention is performed, the compensatory mechanisms to overcome the increase in wall stress could eventually become insufficient, leading to a progressive reduction in LVEF. Inverse correlations between LVEF and LV myocardial fibrosis have been demonstrated by Hein *et al.*,<sup>30</sup> suggesting that LV myocardial fibrosis significantly contributes to the progression of LV systolic dysfunction. These observations demonstrate that the LV response to valvular afterload occurs through a continuous spectrum of LV remodelling and emphasize the importance of a timely intervention at the level of the aortic valve, maybe even when AS severity is still moderate.

### Prognostic value of LV remodelling patterns in moderate AS

Although the traditional focus of AS assessment has been on the valve, it is increasingly acknowledged that AS is not only a disease of the aortic valve but also of the LV. Current guidelines strongly recommend AVR for patients with severe AS who are either symptomatic or develop LV systolic dysfunction, demonstrating that the decision to intervene is ultimately driven by the condition of the LV myocardium and not by the valve. This study shows that LV remodelling in patients with moderate AS already varies considerably and that different patterns of LV remodelling have a different impact on

prognosis. Interestingly, only concentric hypertrophy remained independently associated with all-cause mortality after adjusting for other clinical and echocardiographic variables. The observation that concentric hypertrophy is associated with outcomes in patients with a pressure overloaded LV has been previously demonstrated. Koren *et al.*<sup>37</sup> showed that patients with essential arterial hypertension and concentric hypertrophy had a two-fold increase in cardiovascular deaths compared to patients with eccentric hypertrophy. Similarly, in 436 hypertensive patients, Muiesan *et al.*<sup>13</sup> demonstrated that cardiovascular morbidity and mortality were significantly higher in patients with concentric hypertrophy compared to patients with eccentric hypertrophy. In addition, Capoulade *et al.*<sup>15</sup> demonstrated that LV concentric hypertrophy was independently associated with an increased risk of mortality in patients with severe AS. Our data expand on these results by demonstrating a strong, independent link between concentric LV hypertrophy and outcomes in a large population of patients with moderate AS.

In this study, patients with concentric hypertrophy had higher peak aortic jet velocities and mean aortic pressure gradients with a non-significant trend to a smaller AVA compared to patients with a normal geometry. These observations suggest that AS severity might need to be considered as a continuous variable, with each incremental increase in AS severity imposing an additional pressure load on the LV, thereby facilitating LV remodelling. In addition, it is important to notify that LV remodelling is not only a manifestation of the underlying AS, but rather an expression of the complex interaction between the LV myocardium, valvular afterload, and arterial afterload. In the current study, patients with moderate AS had a high prevalence of concomitant cardiovascular comorbidities, such as diabetes mellitus, arterial hypertension, coronary artery disease, and significant concomitant aortic and mitral regurgitation, which are all known to have an impact on LV remodelling (and the development of LV fibrosis) as well.<sup>13,37,38</sup> Nonetheless, it has been demonstrated that in



patients with a combination of moderate AS and reduced systemic arterial compliance, global LV afterload is equivalent, and has similar adverse effects on LV remodelling, compared to patients with isolated severe AS.<sup>39</sup> Any significant decrease in LV afterload may therefore contribute to the improvement of LV remodelling and future trials are needed to investigate if treating moderate AS in well-selected patients with a markedly increased valvulo-arterial impedance could reverse LV remodelling and improve outcomes.

## Clinical implications

Current guidelines recommend AVR for patients with severe AS who are symptomatic or in whom LV systolic dysfunction develops in the absence of symptoms.<sup>8,9</sup> However, as shown in this study, the clinical and echocardiographic presentation of patients with moderate AS already varies considerably with a large proportion of patients showing marked LV remodelling. Because different patterns of LV remodelling are closely related to prognosis, characterizing these patterns in patients with moderate AS is important in daily clinical practice. Whether these data should expand current indications for AVR before progression to severe AS and outweigh the risk of intervention remains uncertain, especially considering the high prevalence of concomitant cardiovascular comorbidities. Nonetheless, future trials investigating the risk-to-benefit ratio of AVR in patients with moderate AS at increased risk appear warranted. The PROGRESS Trial (A Prospective, Randomized, Controlled Trial to Assess the Management of Moderate Aortic Stenosis by Clinical Surveillance or Transcatheter Aortic Valve Replacement) (NCT 04889872) is currently recruiting patients to explore the hypothesis that transcatheter AVR could improve outcomes in patients with moderate AS.

## Limitations

The limitations of this study are inherent in its retrospective design. Evaluation of LVMI according to Devereux's formula is based on geometrical assumptions and may not always be applicable (e.g. in case of major LV distortions, such as myocardial infarction). Echocardiographic measurements were not performed in an independent echocardiographic laboratory. A time span of 18 years was used for inclusion of patients to acquire the large cohort as presented. Specific indications for surgery during follow-up were not recorded in the present database. However, follow-up was performed by cardiologists with expertise in valvular heart disease and surgical decisions were made in accordance to current practice guidelines. Patients had a high prevalence of concomitant cardiovascular comorbidities, which could have an impact on LV remodelling. In addition, measuring the valvulo-arterial impedance could provide additional information, but the retrospective design precluded obtaining the necessary data for its calculation. All-cause mortality was chosen as the primary endpoint because the exact cause of death was not systematically recorded.

## Conclusions

Different patterns of LV remodelling are observed in patients with moderate AS with LV concentric hypertrophy being independently associated with all-cause mortality at long-term follow-up. Risk stratification according to the different patterns of LV remodelling may

help to identify patients with moderate AS who are at increased risk of adverse events and may benefit from close monitoring and follow-up.

## Supplementary data

Supplementary data are available at *European Heart Journal - Cardiovascular Imaging* online.

## Funding

J.S. received funding from the European Society of Cardiology (ESC Training Grant App000064741). S.C.B. received funding from the European Society of Cardiology (ESC Research Grant App000080404). S.M.P. received funding from the European Society of Cardiology (ESC Training Grant T-2018-17405).

**Conflict of interest:** The Department of Cardiology of the Leiden University Medical Centre received unrestricted research grants from Abbott Vascular, Bayer, Biotronik, Bioventrix, Boston Scientific, Edwards Lifesciences, GE Healthcare, and Medtronic. J.J.B. received speaker fees from Abbott Vascular. N.A.M. received speaker fees from Abbott Vascular and GE Healthcare. V.D. received speaker fees from Abbott Vascular, Edwards Lifesciences, MSD, and GE Healthcare. The remaining authors have nothing to disclose.

## Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

## References

1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Bärwolf C, Leung OW et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. *Eur Heart J* 2003;**24**:1231–43.
2. Osnabrugge RLJ, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. *J Am Coll Cardiol* 2013;**62**:1002–12.
3. Horstkotte D, Loogen F. The natural history of aortic valve stenosis. *Eur Heart J* 1988;**9** Suppl E:57–64.
4. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve disease. *Eur Heart J* 1987;**8**:471–83.
5. Schwarz F, Baumann P, Manthey J, Hoffmann M, Schuler G, Mehmel HC et al. The effect of aortic valve replacement on survival. *Circulation* 1982;**66**:1105–10.
6. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T et al. Poor long-term survival in patients with moderate aortic stenosis. *J Am Coll Cardiol* 2019;**74**:1851–63.
7. Stassen J, Butcher S, Hirasawa K et al. Prognostic value of left ventricular ejection fraction and symptom severity in patients with moderate aortic stenosis. *Eur Heart J Cardiovasc Imaging* 2021. <https://doi.org/10.1093/eurheartj/ehab724>.1570.
8. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *Circulation* 2021;**143**: e72–227.
9. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2021;ehab395. doi: 10.1093/eurheartj/ehab395.
10. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. *J Am Coll Cardiol* 2011;**58**:1271–9.
11. Lee H, Park J-B, Yoon YE, Park E-A, Kim H-K, Lee W et al. Noncontrast myocardial T1 mapping by cardiac magnetic resonance predicts outcome in patients with aortic stenosis. *JACC Cardiovasc Imaging* 2018;**11**:974–83.
12. Nauta JF, Hummel YM, Tromp J, Ouwkerk W, van der Meer P, Jin X et al. Concentric vs. eccentric remodelling in heart failure with reduced ejection

- fraction: clinical characteristics, pathophysiology and response to treatment. *Eur J Heart Fail* 2020;**22**:1147–55.
13. Muesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S *et al*. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. *Hypertension* 2004;**43**:731–8.
  14. Verma A, Meris A, Skali H, Ghali JK, Arnold JMO, Bourgoun M *et al*. Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study. *JACC Cardiovasc Imaging* 2008;**1**:582–91.
  15. Capoulade R, Clavel M-A, Le Ven F, Dahou A, Thébault C, Tastet L *et al*. Impact of left ventricular remodelling patterns on outcomes in patients with aortic stenosis. *Eur Heart J Cardiovasc Imaging* 2017;**18**:1378–87.
  16. Treibel TA, Badiani S, Lloyd G, Moon JC. Multimodality imaging markers of adverse myocardial remodeling in aortic stenosis. *JACC Cardiovasc Imaging* 2019;**12**:1532–48.
  17. Biner S, Rafique AM, Goykhman P, Morrissey RP, Naghi J, Siegel RJ *et al*. Prognostic value of E/E' ratio in patients with unoperated severe aortic stenosis. *JACC Cardiovasc Imaging* 2010;**3**:899–907.
  18. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL *et al*. Reduced left ventricular ejection fraction in patients with aortic stenosis. *J Am Coll Cardiol* 2018;**71**:1313–21.
  19. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV *et al*. Effect of left ventricular ejection fraction on postoperative outcome in patients with severe aortic stenosis undergoing aortic valve replacement. *Circ Cardiovasc Imaging* 2015;**8**:e002917.
  20. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L *et al*. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2015;**28**:1–39.
  21. Ito S, Miranda WR, Nkomo VT, Boler AN, Pislaru SV, Pellikka PA *et al*. Prognostic risk stratification of patients with moderate aortic stenosis. *J Am Soc Echocardiogr* 2021;**34**:248–56.
  22. Zhu D, Ito S, Miranda WR, Nkomo VT, Pislaru SV, Villarraga HR *et al*. Left ventricular global longitudinal strain is associated with long-term outcomes in moderate aortic stenosis. *Circ Cardiovasc Imaging* 2020;**13**:e009958.
  23. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S *et al*. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *Eur Heart J Cardiovasc Imaging* 2017;**18**:254–75.
  24. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA *et al*. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. *J Am Soc Echocardiogr* 2017;**30**:303–71.
  25. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T *et al*. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr* 2016;**29**:277–314.
  26. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K *et al*. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* 2010;**23**:685–713; quiz 86–8.
  27. Beach JM, Mihaljevic T, Rajeswaran J, Marwick T, Edwards ST, Nowicki ER *et al*. Ventricular hypertrophy and left atrial dilatation persist and are associated with reduced survival after valve replacement for aortic stenosis. *J Thorac Cardiovasc Surg* 2014;**147**:362–9.e8.
  28. Rassi AN, Pibarot P, Elmariah S. Left ventricular remodelling in aortic stenosis. *Can J Cardiol* 2014;**30**:1004–11.
  29. Cecchi F, Sgalambro A, Baldi M, Sotgia B, Antonucci D, Camici PG *et al*. Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy. *J Cardiovasc Transl Res* 2009;**2**:452–61.
  30. Hein S, Arnon E, Kostin S, Schönburg M, Elsässer A, Polyakova V *et al*. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. *Circulation* 2003;**107**:984–91.
  31. Puls M, Beuthner BE, Topci R, Vogelgesang A, Bleckmann A, Sitte M *et al*. Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis. *Eur Heart J* 2020;**41**:1903–14.
  32. Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A *et al*. Extracellular myocardial volume in patients with aortic stenosis. *J Am Coll Cardiol* 2020;**75**:304–16.
  33. Kupari M, Turto H, Lommi J. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? *Eur Heart J* 2005;**26**:1790–6.
  34. Duncan AI, Lowe BS, Garcia MJ, Xu M, Gillinov AM, Mihaljevic T *et al*. Influence of concentric left ventricular remodeling on early mortality after aortic valve replacement. *Ann Thorac Surg* 2008;**85**:2030–9.
  35. Cioffi G, Faggiano P, Vizzardi E, Tarantini L, Cramariuc D, Gerds E *et al*. Prognostic effect of inappropriately high left ventricular mass in asymptomatic severe aortic stenosis. *Heart* 2011;**97**:301–7.
  36. Weidemann F, Herrmann S, Störk S, Niemann M, Frantz S, Lange V *et al*. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. *Circulation* 2009;**120**:577–84.
  37. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann Intern Med* 1991;**114**:345–52.
  38. Lindman BR, Arnold SV, Madrazo JA, Zajarías A, Johnson SN, Pérez JE *et al*. The adverse impact of diabetes mellitus on left ventricular remodeling and function in patients with severe aortic stenosis. *Circ Heart Fail* 2011;**4**:286–92.
  39. Briand M, Dumesnil JG, Kadem L, Tongue AG, Rieu R, Garcia D *et al*. Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. *J Am Coll Cardiol* 2005;**46**:291–8.